Inspiralis Competitors and Similar CompaniesClear all

Inspiralis's competitors and similar companies include Viroclinics Biosciences, Biophyll, iNtRON Biotechnology and Gilead Sciences.

	Inspiralis Inspiralis is a company that supplies topoisomerase products to the pharmaceutical industries and academia.	Viroclinics Biosciences Viroclinics Biosciences (Viroclinics-DDL) is a diagnostic and clinical trial operation service company.	Biophyll Biophyll is a company sourcing, manufacturing, and developing biological products of animal, human, and plant origin.	iNtRON Biotechnology iNtRON Biotechnology is a research and development company developing bio-drugs and conducting clinical studies.	Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
Founding Date	Founding Date 1995	Founding Date 2001	Founding Date 2007	Founding Date 1999	Founding Date 1987
Type	Type Private	Type Subsidiary	Type Private	Type Public	Type Public
Tags	Tags Manufacturing & Industrial biotech clinical research distribution pharma	Tags Manufacturing & Industrial biotech clinical research pharma	Tags Manufacturing & Industrial biotech clinical research pharma	Tags Manufacturing & Industrial biotech clinical research pharma	Tags Manufacturing & Industrial biotech clinical research drug development pharma
Locations	Locations Norwich, GB HQ	Locations Rotterdam, NL HQ	Locations Dietersburg, DE HQ	Locations Seongnam-si, KR HQ	Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more
Employees	Employees 8	Employees 991% decrease	Employees 2	Employees 76	Employees 18,0006% increase
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ₩6.4b (FY, 2024)	Revenue (est.) $29.4b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods ₩1.5b (FY, 2024)	Cost of goods $6.2b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit ₩5b (FY, 2024)	Gross profit $23.2b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income (₩2.6b) (FY, 2024)	Net income $8.5b (FY, 2025)